Reduced glutathione (GSH)

Reduced glutathione (GSH) is a vital tripeptide composed of glutamate, cysteine, and glycine, serving as the primary endogenous antioxidant and redox buffer in eukaryotic cells (PubChem, 2024). It plays a fundamental role in protecting cells from oxidative stress by neutralizing reactive oxygen species and is essential for the detoxification of various drugs and toxins through conjugation reactions catalyzed by glutathione S-transferases (NIH StatPearls, 2023). In clinical settings, GSH levels are a critical determinant of cellular health; depletion is associated with neurodegenerative diseases like Parkinson's and Alzheimer's, as well as liver damage and chronic inflammation (PubMed, PMID: 24791752). From a therapeutic perspective, GSH is targeted by increasing its synthesis using precursors like N-acetylcysteine to treat conditions like acetaminophen toxicity or by depleting its levels in oncology to overcome drug resistance in cancer cells (Journal of Biological Chemistry, 2013). GSH also acts as a cofactor for several enzymes, including glutathione peroxidase, which reduces lipid hydroperoxides. Understanding the dynamics of the GSH/GSSG (oxidized glutathione) ratio is essential for monitoring the redox state of tissues and the efficacy of antioxidant therapies (Wikipedia, 2024).

Other names

GlutathioneL-Glutathionegamma-L-Glutamyl-L-cysteinyl-glycineGSH-red

Reduced glutathione acts as a direct scavenger of reactive oxygen species (ROS) and a nucleophilic substrate for glutathione S-transferases (GSTs) to neutralize and eliminate electrophilic xenobiotics. In therapeutic contexts, drugs like N-acetylcysteine serve as precursors to increase GSH synthesis, while others like buthionine sulfoximine are used to deplete GSH levels to sensitize cancer cells to chemotherapy or radiation.